A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts

Liver Transplantation

Volumn 15, Issue 3, 2009, Pages 330-340

  Alabraba, Edward ^a,b   Nightingale, Peter ^a   Gunson, Bridget ^a,b   Hubscher, Stefan ^b,c   Olliff, Simon ^a   Mirza, Darius ^a,b   Neuberger, James ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; MESALAZINE; OKT 3; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; URSODEOXYCHOLIC ACID;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; COLON RESECTION; CYTOMEGALOVIRUS; DONOR RISK INDEX; DONOR SELECTION; DRUG MEGADOSE; ENTERITIS; EXTENDED DONOR CRITERIA; EXTENDED DONOR CRITERIA GRAFT; FEMALE; FOLLOW UP; GRAFT FAILURE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER GRAFT; LIVER GRAFT REJECTION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RECURRENT PRIMARY SCLEROSING CHOLANGITIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; CADAVER; CHOLANGITIS, SCLEROSING; COLECTOMY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEX CHARACTERISTICS; SURVIVAL ANALYSIS; SURVIVORS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 67649232094     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21679     Document Type: Article

References (43)

1. Vera A, Moledina S, Gunson B, Hubscher S, Mirza D, Olliff S, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002;360:1943-1944.
2. Khettry U, Keaveny A, Goldar-Najafi A, Lewis WD, Pomfret EA, Pomposelli JJ, et al. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum Pathol 2003;34:1127-1136.
3. Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003;9:727-732.
4. Brandsaeter B, Schrumpf E, Bentdal O, Brabrand K, Smith HJ, Abildgaard A, et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl 2005;11:1361-1369.
5. Cholongitas E, Shusang V, Papatheodoridis GV, Marelli L, Manousou P, Rolando N, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008;14:138-143.
6. Alexander J, Lord JD, Yeh MM, Cuevas C, Bakthavatsalam R, Kowdley KV. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008;14:245-251.
7. Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl 2008;14:181-185.
8. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, Porayko MK, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999;29:1050-1056.
9. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007;102:107-114.
10. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-615.
11. Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F, Czaja A, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006;44:489-501.
12. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008;21:459-465.
13. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12:1813-1824.
14. Tekin K, Imber CJ, Atli M, Gunson BK, Bramhall SR, Mayer D, et al. A simple scoring system to evaluate the effects of cold ischemia on marginal liver donors. Transplantation 2004;77:411-416.
15. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783-790.
16. Axelrod DA, Schnitzler M, Salvalaggio PR, Swindle J, Abecassis MM. The economic impact of the utilization of liver allografts with high donor risk index. Am J Transplant 2007;7:990-997.
17. Seyam M, Neuberger JM, Gunson BK, Hubscher SG. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transpl 2007; 13:966-974.
18. Harrison RF, Davies MH, Neuberger JM, Hubscher SG. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis? Hepatology 1994;20:356-361.
19. Loftus EV Jr, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91-96.
20. Helzberg JH, Petersen JM, Boyer JL. Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology 1987;92:1869-1875.
21. Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan - analysis of 192 cases. J Gastroenterol 1997;32: 134-137.
22. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002;359:150-157.
23. Grant AJ, Lalor PF, Hubscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 2001;33:1065-1072.
24. Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, Hubscher SG, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9 gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004; 200:1511-1517.
25. Lalor PF, Edwards S, McNab G, Salmi M, Jalkanen S, Adams DH. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol 2002;169:983-992.
26. Salmi M, Kalimo K, Jalkanen S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med 1993;178:2255-2260.
27. Kartheuser AH, Dozois RR, LaRusso NF, Wiesner RH, Ilstrup DM, Schleck CD. Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy. Mayo Clin Proc 1996;71:748-756.
28. Stahlberg D, Veress B, Tribukait B, Broome U. Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum 2003; 46:770-778.
29. Rubin DT, Parekh N. Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations. Curr Treat Options Gastroenterol 2006;9:211-220.
30. Abdelrazeq AS, Kandiyil N, Botterill ID, Lund JN, Reynolds JR, Holdsworth PJ, et al. Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis 2008;10:805-813
31. Walker M, Radley S. Adenocarcinoma in an ileoanal pouch formed for ulcerative colitis in a patient with primary sclerosing cholangitis and a liver transplant: report of a case and review of the literature. Dis Colon Rectum 2006;49: 909-912.
32. Baan CC, van der Mast BJ, Klepper M, Mol WM, Peeters AM, Korevaar SS, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005;80:110-117.
33. Segundo DS, Ruiz JC, Izquierdo M, Fernandez-Fresnedo G, Gomez-Alamillo C, Merino R, et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4CD25FOXP3 regulatory T cells in renal transplant recipients. Transplantation 2006;82:550-557.
34. Harnois DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-1562.
35. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-907.
36. Smith T, Befeler AS. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Curr Gastroenterol Rep 2007;9:54-59.
37. Charatcharoenwitthaya P, Angulo P, Enders FB, Lindor KD. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology 2008;47:133-142.
38. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-893.
39. Chapman RW, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut 1983;24:38-41.
40. Schrumpf E, Fausa O, Forre O, Dobloug JH, Ritland S, Thorsby E. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol 1982;17:187-191.
41. Briceno J, Ciria R, Pleguezuelo M, Naranjo A, Sanchez-Hidalgo J, Ruiz-Rabelo J, et al. Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc 2007;39:2297-2299.
42. Botha JF, Thompson E, Gilroy R, Grant WJ, Mukherjee S, Lyden ER, et al. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int 2007;27:758-763.
43. Liermann Garcia RF, Evangelista GC, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001;33:22-27.